广西河池化工股份有限公司 2022 年第一季度报告全文 证券代码：000953 证券简称：河化股份 公告编号：2022-021 广西河池化工股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 40,969,366.74 | 46,757,837.67 | -12.38% | | 归属于上市公司股东的净利润（元） | -1,431,517.79 | 5,459,9 ...

Financial Performance - The company's operating revenue for 2021 was ¥162,273,039.66, a decrease of 33.36% compared to ¥243,512,663.64 in 2020[20] - The net profit attributable to shareholders for 2021 was ¥10,018,330.39, down 67.62% from ¥30,939,202.60 in the previous year[20] - Basic earnings per share for 2021 were ¥0.03, a decline of 66.67% from ¥0.09 in 2020[21] - The net cash flow from operating activities decreased by 90.00%, amounting to ¥6,710,748.57 compared to ¥67,130,814.12 in 2020[21] - The company reported a total of ¥7.72 million in non-recurring gains and losses for 2021, a significant recovery from a loss of approximately ¥7.54 million in 2020[27] - The company achieved a total operating revenue of ¥162,273,039.66 in 2021, a decrease of 33.36% compared to the previous year[43] - The net profit attributable to shareholders was ¥10,018,330.39, down 67.62% year-on-year[43] - The pharmaceutical intermediates segment generated ¥89,702,497.45, accounting for 55.28% of total revenue, reflecting a 41.67% decline from 2020[45] - The fertilizer business contributed ¥68,291,410.11, representing 42.08% of total revenue, with a decrease of 22.49% year-on-year[45] Business Transformation and Strategy - The company has undergone a significant business transformation since 2020, shifting its focus to the research, production, and sales of chemical raw materials and pharmaceuticals[18] - The company emphasizes the importance of market conditions in achieving its operational goals and future plans[4] - The company is focused on the R&D and production of pharmaceutical intermediates, with a strong emphasis on new product development and process improvement[35] - The company utilizes a centralized procurement model to improve cost efficiency and reduce supply chain volatility[37] - The production strategy includes both general production based on sales forecasts and customized production according to client specifications[37] Market and Demand - The demand for chloroquine side chains surged in 2020 due to the COVID-19 pandemic, leading to increased product demand and prices, although the market normalized in 2021[32] - The company faced challenges due to high raw material prices and unstable energy supply, impacting production cycles and costs[42] - The domestic revenue was ¥112,500,990.05, down 31.98% year-on-year, while overseas revenue decreased by 36.28% to ¥49,772,049.61[45] Research and Development - The company’s R&D expenses in 2021 were ¥7,703,278.92, a decrease of 9.24% compared to ¥8,487,368.41 in 2020, while the R&D expenses accounted for 4.75% of operating revenue[56] - The company completed the optimization of several new processes, including methyl silane and valproic acid, aiming for industrial production and new economic growth points[56][57] - The number of R&D personnel decreased by 7.14% from 56 in 2020 to 52 in 2021, while the proportion of R&D personnel increased from 27.18% to 32.53%[57] Governance and Compliance - The company has established a robust internal management system to ensure compliance with laws and regulations, enhancing governance standards[82] - The company prioritizes transparent information disclosure, ensuring all shareholders have equal access to relevant information[85] - The company actively manages investor relations through various communication channels, fostering a positive relationship with investors[85] - The company has maintained effective internal control over financial reporting without any significant deficiencies or important deficiencies[129] - The internal control audit report issued on April 30, 2022, confirmed that the company maintained effective internal controls in all material respects as of December 31, 2021[134] Shareholder Relations - The company held two shareholder meetings during the reporting period, ensuring equal rights for all shareholders, particularly minority shareholders[83] - The annual shareholders' meeting had a participation rate of 30.29% on May 18, 2021[88] - The first extraordinary shareholders' meeting had a participation rate of 43.76% on September 14, 2021[89] - The company has not reported any penalties from securities regulatory agencies for its current and recently departed directors, supervisors, and senior management[108] Environmental and Social Responsibility - The company has invested in environmental protection facilities and improved production processes to achieve energy conservation and emission reduction goals[147] - The company has not faced any administrative penalties related to environmental issues during the reporting period[145] - The company has not initiated any poverty alleviation or rural revitalization projects during the reporting period[148] Future Outlook - The company plans to enhance cooperation with downstream pharmaceutical clients and increase investment in technology development and business expansion[74] - New product development will focus on T51, T22, and T62 intermediates, with efforts to accelerate their market introduction[75] - The company anticipates risks from drug procurement policies that may lead to price declines for intermediate products, prompting a need for cost control and quality improvement[77] - The company has provided a revenue guidance of CNY 1.8 billion for the fiscal year 2022, which reflects an expected growth of 20%[95] Related Party Transactions and Commitments - The company has committed to avoid any form of fund occupation or illegal appropriation of assets from the listed company[153] - The company has pledged to ensure that no direct or indirect means will be used to seek control over the board of directors of the listed company[153] - The commitments made by the actual controller will remain valid unless they cease to be the controlling shareholder[150] - The company has undertaken to minimize related transactions and ensure they are conducted at market prices[150] Employee and Management Information - The total number of employees at the end of the reporting period is 182, with 16 in the parent company and 166 in major subsidiaries[122] - The company has a complete business operation system and does not engage in substantial competition with its controlling shareholders[87] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 2.0772 million CNY[111]

广西河池化工股份有限公司 2021 年第三季度报告 证券代码：000953 证券简称：河化股份 公告编号：2021-039 广西河池化工股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 增减 | | 比上年同期增减 | | 营业收入（元） | 40,097,269.40 | 24.06% | 133,381,231.81 | -40.01% ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥93,283,962.41, a decrease of 50.91% compared to ¥190,023,890.74 in the same period last year[20]. - The net profit attributable to shareholders was ¥2,856,763.21, down 93.73% from ¥45,572,911.22 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥1,751,745.52, a decline of 96.15% compared to ¥45,441,914.64 in the previous year[20]. - The net cash flow from operating activities was ¥7,375,714.21, representing an 83.71% decrease from ¥45,285,557.86 in the same period last year[20]. - Basic earnings per share were ¥0.0078, down 93.95% from ¥0.1290 in the previous year[20]. - The company's revenue for the reporting period was ¥93.28 million, a decrease of 50.91% compared to ¥190.02 million in the same period last year[36]. - The net profit for the reporting period was ¥334.96 million, down 93.18% from the previous year[36]. - The gross profit margin for the pharmaceutical intermediates segment was 44.64%, down 17.19% year-on-year, while the gross profit margin for the fertilizer business was 1.43%, down 0.20% year-on-year[40]. - The net cash flow from operating activities decreased by 83.71% to ¥7,375,714.21, primarily due to a reduction in sales revenue[40]. - The company's total operating revenue for the reporting period was ¥93,283,962.41, a decrease of 50.91% compared to ¥190,023,890.74 in the same period last year[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥382,243,744.99, an increase of 1.58% from ¥376,292,912.19 at the end of the previous year[20]. - The net assets attributable to shareholders at the end of the reporting period were ¥169,847,014.84, up 1.71% from ¥166,990,251.63 at the end of the previous year[20]. - The company's total assets included cash and cash equivalents of ¥80,607,138.98, representing 21.09% of total assets, primarily due to the redemption of bank wealth management products[45]. - The company's total liabilities increased to CNY 196,468,125.83 from CNY 193,866,917.27, reflecting a growth of about 0.8%[122]. - The company's non-current assets decreased to CNY 245,166,701.57 from CNY 248,794,081.79, showing a decline of approximately 1.1%[121]. - The company's total liabilities at the end of the period were CNY 701,900,568.72, indicating a high leverage ratio[144]. Research and Development - The company continues to conduct small-scale research and pilot projects, including ongoing optimization of the T53 (Nebivolol Epoxide) process to reduce raw material costs[36]. - The company has developed new processes for T55 (Valproic Acid) and T57 (N-desmethylclobazam), with T57 samples already sent to customers for validation[36]. - The company emphasizes R&D and has a dedicated project management system to improve efficiency and reduce costs[30]. - Research and development expenses amounted to ¥3,850,668.12, a decrease of 18.18% from ¥4,706,454.31 in the previous year[40]. - The company's research and development expenses for the first half of 2021 were CNY 3,850,668.12, a decrease of 18.19% from CNY 4,706,454.31 in the first half of 2020[128]. Market and Sales - Domestic sales accounted for 73.53% of total revenue, amounting to ¥68,588,445.33, while overseas sales accounted for 26.47%, totaling ¥24,695,517.08, reflecting decreases of 47.04% and 59.20% respectively[39]. - The company has a high market share and quality-leading products, with self-operated import and export rights[32]. - The company has a flexible production model that allows for customization based on client needs, particularly for Vitamin D3 intermediates[31]. - The company has maintained a stable relationship with major clients, which is crucial for its revenue stability[58]. Environmental and Regulatory Compliance - The company emphasizes environmental protection and has taken measures to control pollution during production processes[55]. - The company has completed the construction of pollution control facilities, including a waste gas collection and treatment system with a design capacity of 30,000 m³/h and a wastewater treatment plant with a design capacity of 500 t/d[69]. - The total discharge of chemical oxygen demand (COD) is 1.55 t/a, which is below the approved discharge limit of 2.57 t/a, indicating no exceedance[69]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[73]. - The company has submitted a self-monitoring plan for environmental protection, which includes monitoring of wastewater, waste gas, and noise pollution[72]. Corporate Governance - The company has not made any changes to its board of directors or senior management during the reporting period[64]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[81]. - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[77]. - The semi-annual financial report has not been audited[79]. Financial Management - The company has a receivable from related parties amounting to 10,683.57 million CNY, with an interest rate of 4.35%[87]. - The company has a payable to related parties totaling 2,282.93 million CNY, also at an interest rate of 4.35%[87]. - The company utilized related party borrowings primarily for short-term cash flow management, ensuring operational stability without impacting financial results[87]. - The company has invested 7,650 million CNY in bank wealth management products, with an outstanding balance of 704.6 million CNY[95]. - The company reported a total share count of 366,122,195, with 25,862,068 shares released from lock-up on March 26, 2021[101]. Future Outlook - The company plans to strengthen its market expansion and product development strategies to mitigate risks associated with high customer concentration[58]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[144].

证券代码：000953 证券简称： *ST 河化 公告编号：2021-017 广西河池化工股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，广西河池化工股份有限公司 （以下简称"公司"）将参加由广西上市公司协会、深圳市全景网络 有限公司共同举办的"2021 年广西地区上市公司投资者网上集体接 待日活动"，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台举行，投资者可以登陆"全景•投资者关系互动平台"网站 （http：//ir.p5w.net）参与公司本次投资者集体接待日活动，活动 时间为 2021 年 5 月 21 日（星期五）15:30 至 17:00。 届时公司董事长总经理覃宝明先生、财务总监卢勇帐先生、董事 会秘书覃丽芳女士（如有特殊情况，参会人员可能进行调整）将通过 网络在线问答互动的形式，与投资者就公司治理、发展经营情况、融 资情况和可持续发展等投资者关注的问题进行交流。期间，公司高管 将全程在线，通过全景网投资者关系互动平台 ...

广西河池化工股份有限公司 2021 年第一季度报告全文 广西河池化工股份有限公司 2021 年第一季度报告 2021 年 04 月 1 广西河池化工股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人施伟光、主管会计工作负责人卢勇帐及会计机构负责人(会计主 管人员)雷吉声明：保证季度报告中财务报表的真实、准确、完整。 2 广西河池化工股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 46,757,837.67 | 59,919,555.56 | -21.97% | | 归属于上市公司股东的净利润（元） | 5,459,994.36 | 8,672,939. ...

Financial Performance - The company's operating revenue for 2020 was CNY 243,512,663.64, representing a 75.62% increase compared to CNY 138,660,130.33 in 2019[19] - The net profit attributable to shareholders for 2020 was CNY 30,939,202.60, a significant turnaround from a loss of CNY 60,916,555.09 in 2019, marking a 150.79% improvement[19] - The net cash flow from operating activities reached CNY 67,130,814.12, a remarkable increase of 703.99% from a negative cash flow of CNY 11,114,589.37 in the previous year[19] - The basic earnings per share for 2020 was CNY 0.090, compared to a loss of CNY 0.210 per share in 2019, reflecting a 142.86% increase[20] - The total assets at the end of 2020 amounted to CNY 376,292,912.19, which is a 9.17% increase from CNY 344,683,621.33 at the end of 2019[20] - The net assets attributable to shareholders surged to CNY 166,990,251.63, a 612.73% increase from CNY 23,429,825.28 in 2019[20] - The weighted average return on net assets for 2020 was 25.12%, a notable improvement from 0.00% in 2019[20] - The company reported a significant reduction in financial expenses by 64.63% to CNY 8.70 million due to the repayment of CNY 420 million in loans following the asset restructuring in 2019[56] Business Transformation - The company underwent a significant asset restructuring in 2020, changing its main business to the research, production, and sales of chemical raw materials and pharmaceuticals[17] - The company achieved a transformation from traditional fertilizer manufacturing to the research, production, and sales of pharmaceutical intermediates through a major asset restructuring in 2020[80] - The company underwent a major asset restructuring in December 2019, selling less profitable urea production assets and acquiring Nansong Pharmaceutical to enter the pharmaceutical intermediate sector[28] - The company is actively pursuing new product development and market expansion in the pharmaceutical sector, focusing on various intermediate products[57] Revenue Breakdown - The pharmaceutical intermediates segment generated CNY 153.77 million, accounting for 63.15% of total revenue, with a gross margin of 57.99%[45] - The fertilizer business revenue decreased by 35% to CNY 88.10 million, with a gross margin of only 1.66%[45] - The revenue from pharmaceutical intermediates was CNY 153.77 million in 2020, a 57.45% increase from CNY 97.66 million in 2019, with a gross margin of 57.99%[52] Cash Flow and Investments - The net cash flow from operating activities increased by 703.99% to ¥67,130,814.12 compared to a loss of ¥11,114,589.37 in the previous year[59] - Total cash inflow from operating activities rose by 73.82% to ¥268,943,770.14, driven by increased demand for products due to the COVID-19 pandemic[60] - Total cash outflow from operating activities increased by 21.69% to ¥201,812,956.02, primarily due to higher procurement of raw materials[60] - Cash inflow from investment activities surged significantly, with a reported increase of 25,824,075,150.00% to ¥258,240,752.50, attributed to the inclusion of Nansong Pharmaceutical in the consolidation scope[60] Shareholder and Dividend Information - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company reported a net profit attributable to ordinary shareholders of 30,939,202.60 in 2020, with a cash dividend payout ratio of 0.00%[86] - No cash dividends were distributed in the reporting period, and the company plans not to issue cash dividends or bonus shares in the upcoming year[87] - The company has not proposed any profit distribution or capital reserve transfer plans in recent years due to negative retained earnings[85] Market Presence and Strategy - The company expanded its market presence, with domestic sales accounting for 67.92% of total revenue and international sales contributing 32.08%[45] - The sales strategy includes leveraging a strong reputation and established sales channels for urea products, allowing for flexible adjustments based on market demand[33] - The company is considering strategic acquisitions to enhance its product portfolio and market presence[175] Research and Development - The company emphasizes new product R&D and has established a dedicated project management system to enhance efficiency and reduce costs[29] - The company has been actively investing in R&D, completing several projects including the production pilot tests for various pharmaceutical intermediates[40] - Research and development expenses amounted to CNY 8.49 million, representing 3.49% of total revenue, marking a 100% increase due to the inclusion of Nansong Pharmaceutical[58] Corporate Governance and Compliance - The company has fulfilled its commitments regarding competition and related transactions as of the reporting period end[88] - The actual controller and shareholders have committed to avoiding and minimizing related party transactions with the company and its subsidiaries[90] - The company is committed to maintaining transparency and fairness in all transactions to protect the legal rights of shareholders[90] Environmental and Social Responsibility - The company has invested in environmental protection facilities and improved production processes to achieve energy conservation and emission reduction[125] - The company has actively participated in social welfare activities, donating over 200,000 CNY for pandemic prevention efforts[125] - The company’s wastewater and waste gas emissions have met industry standards, with no exceedances reported[127][128] Employee and Management Information - The total number of employees in the company is 188, with 128 in production, 5 in sales, 26 in technical roles, 8 in finance, and 19 in administration[189] - The total remuneration for directors, supervisors, and senior management during the reporting period amounts to 184.69 million yuan[188] - The company has established a comprehensive training system for employees, enhancing their professional skills and overall quality[192] Legal and Regulatory Matters - The company is involved in a legal dispute with Alkaloida Chemical Company Zrt regarding overdue payments totaling 673,500.00 USD[106] - The company has no significant penalties or rectification situations during the reporting period[107] - The company reported no major related party transactions during the reporting period[110]

广西河池化工股份有限公司 2020 年第三季度报告全文 广西河池化工股份有限公司 2020 年第三季度报告 2020 年 10 月 1 广西河池化工股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人施伟光、主管会计工作负责人卢勇帐及会计机构负责人(会计主 管人员)雷吉声明：保证季度报告中财务报表的真实、准确、完整。 2 广西河池化工股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 384,118,504.61 | | 344,683,621.33 | 11.44% | | 归属于上市公司股东的净资产 | 182,237,767.04 | ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 190,023,890.74, representing a 117.44% increase compared to CNY 87,392,370.76 in the same period last year[18]. - The net profit attributable to shareholders was CNY 45,572,911.22, a significant turnaround from a loss of CNY 32,484,936.29 in the previous year, marking a 240.29% increase[18]. - The net cash flow from operating activities reached CNY 45,285,557.86, compared to a negative cash flow of CNY 7,869,377.97 in the same period last year, reflecting a 675.47% improvement[18]. - The company achieved operating revenue of CNY 190,023,890.74, a year-on-year increase of 117.44% due to the inclusion of Nansong Pharmaceutical and increased product demand during the pandemic[44]. - Net profit for the first half of 2020 reached CNY 4,912,340, marking a turnaround from a loss in the previous year[42]. - The gross profit margin for the chemical industry segment was 41.07%, reflecting a 41.31% increase year-on-year[47]. - The total comprehensive income for the period was CNY 45,572,911.22, contributing to a significant recovery compared to the previous year's loss of CNY 32,484,936.29[153]. Assets and Liabilities - The company's total assets increased by 14.58% to CNY 394,923,853.30 from CNY 344,683,621.33 at the end of the previous year[18]. - The company's total liabilities decreased from CNY 308,819,964.15 at the end of 2019 to CNY 197,731,624.37, a reduction of about 36.1%[129]. - The total equity attributable to the parent company increased from CNY 23,429,825.28 at the end of 2019 to CNY 181,207,922.52, representing a growth of about 671.5%[130]. - The total liabilities decreased slightly to CNY 701,910,508.72, down from CNY 747,572,879.94, indicating improved financial stability[151]. Research and Development - The company emphasizes new product development and industrialization, implementing a dedicated project management system for R&D[27]. - The company completed the pilot research and development of intermediates for Perindopril and Tofacitinib, and optimized the process for Hydrochloride Fluoxetine and other intermediates[40]. - Research and development expenses amounted to CNY 4,706,454.31, indicating a 100% increase due to the inclusion of Nansong Pharmaceutical's R&D costs[44]. - Research and development expenses for the first half of 2020 were CNY 4,706,454.31, indicating the company's commitment to innovation and product development[135]. Market and Business Strategy - The company plans to focus on the research, production, and sales of pharmaceutical intermediates through its subsidiary, Nansong Pharmaceutical, transitioning from traditional chemical industries to fine chemical sectors[26]. - Nansong Pharmaceutical exports its products to regions including Taiwan, India, and Finland, indicating a strong international market presence[27]. - The company has established a dual-driven model focusing on pharmaceutical intermediates and urea processing sales after acquiring Nansong Pharmaceutical[33]. - The company aims to continue expanding its market presence and enhancing product offerings in the upcoming quarters, focusing on strategic growth initiatives[137]. Cash Flow and Financing - The company's cash flow increased by 200.25% compared to the beginning of the period, primarily due to net cash flow from operations and the sale of bank financial products[32]. - The cash inflow from financing activities for the first half of 2020 was CNY 112,649,995.52, compared to CNY 5,150,000.00 in the same period of 2019, showing a substantial increase[145]. - The net cash flow from financing activities in the first half of 2020 was CNY 66,813,606.63, up from CNY 4,686,397.69 in the first half of 2019, reflecting improved financing conditions[145]. - The company reported a net increase in cash and cash equivalents of CNY 59,953,731.71, a 1,983.57% rise from the previous year[45]. Shareholder Information - The first temporary shareholders' meeting had an investor participation rate of 46.64% on March 20, 2020[68]. - The second temporary shareholders' meeting had an investor participation rate of 45.00% on April 23, 2020[68]. - The annual shareholders' meeting had an investor participation rate of 34.43% on May 20, 2020[68]. - The company has a total of 18,600,000 yuan in entrusted financial management, with an outstanding balance of 604.48 thousand yuan[90]. Environmental and Safety Measures - The company has established safety management protocols to minimize risks associated with hazardous materials used in production[63]. - The company is committed to enhancing its environmental protection measures to comply with increasing regulatory standards[63]. - The company has established an emergency response plan for environmental incidents, which has been filed with the ecological environment bureau[94]. - The company’s wastewater discharge concentration for ammonia nitrogen is 10 mg/L, with a total discharge of 0.121 tons per year[92]. Risks and Challenges - The company faces risks related to policy changes, environmental standards, and high customer concentration, which could impact future performance[62][63][64]. - The company is actively managing raw material price fluctuations to mitigate potential impacts on production costs and profitability[65][66]. Corporate Governance - The company reported no major litigation or arbitration matters during the reporting period[74]. - The company has no non-operating related party debt or significant related party transactions during the reporting period[79][84]. - The company has not experienced any bankruptcy reorganization or significant penalties during the reporting period[73][77]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[78].

广西河池化工股份有限公司 2019 年年度报告全文 广西河池化工股份有限公司 2019 年年度报告 2020 年 04 月 1 广西河池化工股份有限公司 2019 年年度报告全文 第一节 重要提示、目录和释义 所有董事均已出席了审议本报告的董事会会议。 本年度报告中涉及未来计划、发展战略等前瞻性陈述，不构成公司对投资 者的实质承诺，敬请广大投资者注意投资风险。公司已在董事会报告中对公司 未来发展可能面对的风险因素及对策进行了详细阐述，同时经营计划、经营目 标并不代表公司对 2020 年度的盈利预测，能否实现取决于市场状况变化等多种 因素。 公司年报披露不需要遵守特殊行业披露要求。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 5 | | 第三节 | 公司业务概要 | 9 | | 第四节 | 经营情况讨论与分析 | 12 | | 第五节 | 重要事项 | 24 | | 第六节 | 股份变动及股东情况 | 37 | | 第七节 | 优先股相关情况 | 44 | | 第 ...